Patient description: A 57-year-old man was admitted to the clinic because of weight loss and persistent dry cough 4 months ago. Chest computed topography showed bilateral multiple infiltrates in the upper lobes and thickened bronchial walls. There is a documented positive serum MPO-ANCA in his medical record. Transbronchial biopsy revealed necrotic granulomas with multinucleated giant cells and the Wegener's granulomatosis was diagnosed for him. He is treating with corticosteroid and cyclophosphamides since 4 months ago. His Birmingham Vasculitis Activity Score (BVAS) is above 4 since the beginning of his disease. His last physical exam and lab study was performed yesterday and showed the results bellow: A wellbeing, well-nourished man, non-icteric, cooperative and alert Weight: 73 kg Height: 177 BP: 120/80 HR: 90/min RR: 22/min Hgb: 13 g/dl WBC: 8000 /mm3 (Neutrophil: 2700/mm3) Plt: 300000 /ml AST: 40 U/L ALT: 56 U/L Alk P: 147 U/L Bill total: 1.2 mg/dl ESR: 120 mm/hr MPO-ANCA: 153 EU

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Peritoneal Metastasis Histologically confirmed carcinoma of the colon or rectum with synchronous or metachronous peritoneal metastasis. 2. Male and female patients, aged ≥ 18 years. 3. Eastern Cooperative Oncology Group (ECOG) performance score of ≤ 2. 4. Life expectancy ≥ 26 weeks. 5. Neutrophils (absolute count) ≥ 1.5 g/l. 6. Platelet count ≥ 100 g/l. 7. Hemoglobin > 9 g/dL. 8. Total bilirubin ≤ 1.8 mg/dl. 9. Aspartate aminotransferase (AST) and Alanine transaminase (ALT) ≤ 88 U/l (≤ 175 U/l if liver metastases are present). 10. Alkaline phosphatase ≤ 325 U/l (≤ 650 U/l if liver metastases are present). 11. Calculated creatinine clearance > 50 mL/min OR serum creatinine ≤ 1.5 mg/dl. 12. Proteinuria < 2+ by dipstick or urine protein <1 g by 24-hr urine collection. 13. Not pregnant or nursing. 14. Negative pregnancy test (for females of childbearing potential). 15. Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. 16. Written informed consent. 17. General condition considered feasible for major abdominal surgery after systemic chemotherapy. 18. ≤3 liver metastases amenable to curative resection using a minor liver resection  Major surgical procedure or significant traumatic injury within 28 days prior to study enrolment (surgical exploration with diagnostic biopsy/sampling of peritoneal tumor deposits but without bowel resection or comparable surgical procedure is allowed). 2. History of previous cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy. 3. Pregnancy or lactation. 4. Inability or unwillingness to comply with the protocol. 5. Evidence of current extraabdominal metastatic disease. Prior extraabdominal metastatic disease is allowed, provided that it has been curatively resected ≥6 months before study entry and that current staging shows no evidence of disease recurrence. 6. >3 liver metastases or any liver metastases not amenable to upfront curative resection using a minor liver resection. 7. Prior systemic chemotherapy completed ≤3 months before study inclusion. 8. Treatment with any other investigational agent, or participation in another clinical trial within 30 days prior to entering this study. 9. History or evidence upon physical/neurological examination of central nervous system (CNS) disease (unrelated to cancer) unless adequately treated with standard medical therapy (e.g. uncontrolled seizures). 10. Untreated brain metastases, spinal cord compression or primary brain tumors. 11. Past or current history (within the last 2 years prior to treatment start) of other malignancies except colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible). 12. Clinically significant cardiovascular disease, for example cerebrovascular accident (CVA), myocardial infarction (≤12 months before treatment start), unstable angina, New York Heart Association (NYHA) > Class II congestive heart failure (CHF), arrhythmia requiring medication, or uncontrolled hypertension. 13. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of study enrolment. 14. Any previous venous thromboembolism > NCI Common Toxicity for Adverse Effects (CTCAE) Grade 3. 15. Prior history of hypertensive crisis or hypertensive encephalopathy. 16. Evidence of bleeding diathesis or significant coagulopathy. 17. History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess or active gastrointestinal bleeding within 6 months prior to the first study treatment. 18. Known hypersensitivity to any of the study drugs. 19. Serious, non-healing wound, ulcer or bone fracture. 20. Evidence of any other disease, metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that puts the patient at high risk for treatment-related complications. 21. Symptomatic peripheral neuropathy ≥ grade 1 according to the NCI Common Toxicity Criteria